- Home
- ROIV vs VNO Comparison
ROIV vs VNO Comparison
Compare ROIV & VNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- VNO
- Stock Information
- Founded
- ROIV 2014
- VNO 1946
- Country
- ROIV United Kingdom
- VNO United States
- Employees
- ROIV N/A
- VNO N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- VNO Real Estate Investment Trusts
- Sector
- ROIV Health Care
- VNO Real Estate
- Exchange
- ROIV Nasdaq
- VNO Nasdaq
- Market Cap
- ROIV 8.4B
- VNO 7.0B
- IPO Year
- ROIV N/A
- VNO N/A
- Fundamental
- Price
- ROIV $10.76
- VNO $39.49
- Analyst Decision
- ROIV Buy
- VNO Hold
- Analyst Count
- ROIV 4
- VNO 11
- Target Price
- ROIV $17.50
- VNO $38.00
- AVG Volume (30 Days)
- ROIV 5.9M
- VNO 1.3M
- Earning Date
- ROIV 05-29-2025
- VNO 05-05-2025
- Dividend Yield
- ROIV N/A
- VNO 1.88%
- EPS Growth
- ROIV N/A
- VNO 248.25
- EPS
- ROIV N/A
- VNO 0.52
- Revenue
- ROIV $122,585,000.00
- VNO $1,929,890,000.00
- Revenue This Year
- ROIV N/A
- VNO N/A
- Revenue Next Year
- ROIV N/A
- VNO $5.12
- P/E Ratio
- ROIV N/A
- VNO $74.96
- Revenue Growth
- ROIV 140.04
- VNO 2.98
- 52 Week Low
- ROIV $8.73
- VNO $22.42
- 52 Week High
- ROIV $13.06
- VNO $46.63
- Technical
- Relative Strength Index (RSI)
- ROIV 49.33
- VNO 62.03
- Support Level
- ROIV $10.58
- VNO $38.45
- Resistance Level
- ROIV $11.77
- VNO $40.73
- Average True Range (ATR)
- ROIV 0.34
- VNO 1.23
- MACD
- ROIV -0.05
- VNO 0.55
- Stochastic Oscillator
- ROIV 15.13
- VNO 82.23
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.